1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
Key Takeaways
Li-Fraumeni syndrome (TP53) is autosomal dominant with a broad early-onset core tumor spectrum—soft-tissue and osteosarcoma, premenopausal breast cancer, brain tumors, adrenocortical carcinoma, and leukemias—requiring cautious radiation and whole-body surveillance concepts
Von Hippel–Lindau (VHL) features hemangioblastomas, clear-cell renal cell carcinoma, pheochromocytoma, and endolymphatic sac tumors with genotype-informed pheochromocytoma risk counseling
MEN1 (MEN1) centers on parathyroid, pituitary, and enteropancreatic neuroendocrine tumors; MEN2 (RET) centers on medullary thyroid carcinoma with gene-specific prophylactic thyroidectomy timing and pheochromocytoma/hyperparathyroidism patterns by MEN2A/2B
NF1 (NF1) is common, AD, with café-au-lait macules, neurofibromas, and tumor risks including MPNST and optic pathway glioma; NF2-related schwannomatosis (NF2) is dominated by bilateral vestibular schwannomas
Diagnostic strategy matches hallmark tumors to syndrome genes, confirms germline variants, then applies syndrome-specific surveillance—avoid one-size-fits-all “hereditary cancer” scripts
1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
Quick Answer: Match hallmark tumors to genes: TP53 (LFS core cancers), VHL (hemangioblastoma/RCC/pheo), MEN1 (3 Ps), RET (MTC ± pheo/HPTH; MEN2B phenotype), NF1 (CALMs/neurofibromas/MPNST), NF2 (bilateral vestibular schwannomas). All major entities here are autosomal dominant with syndrome-specific surveillance.
After HBOC and Lynch/polyposis, Domain 1C expects fluent recognition of rarer but high-stakes cancer predisposition syndromes. Exam vignettes often give one pathognomonic tumor (adrenocortical carcinoma in a child; bilateral vestibular schwannomas; medullary thyroid cancer) and ask for the gene, inheritance, or next management concept.
Li-Fraumeni Syndrome (LFS) — TP53
| Element | Board-level content |
|---|---|
| Inheritance | Autosomal dominant; TP53 tumor suppressor |
| Core tumors (“classic”) | Soft-tissue sarcoma, osteosarcoma, premenopausal breast cancer, brain tumors, adrenocortical carcinoma (ACC), leukemias |
| Natural history | Very early onset possible; multiple primary cancers common across the lifespan |
| Diagnostic clues | Childhood ACC or choroid plexus carcinoma strongly prompts TP53 evaluation; soft-tissue/osteosarcoma + family pattern |
Management Themes
- Breast surveillance for women often resembles high-risk protocols (MRI; discussion of risk-reducing mastectomy in shared decision-making).
- Whole-body MRI and structured protocols (e.g., “Toronto protocol”–style comprehensive surveillance) appear in LFS care concepts—know that surveillance is multimodal and starts early.
- Radiation sensitivity / second-malignancy concern: avoid unnecessary radiation when alternatives exist; therapeutic radiation decisions are oncology-led but counselors flag the issue.
- Cascade testing has profound psychosocial implications because of childhood risks and reproductive decisions.
Chompret criteria and classic LFS criteria are clinical selection tools—similar in spirit to Amsterdam for Lynch: helpful, incomplete alone.
Von Hippel–Lindau Disease — VHL
VHL is autosomal dominant. Hallmark lesions:
| Tumor / feature | Notes |
|---|---|
| CNS / retinal hemangioblastomas | Cerebellum, brainstem, spine, retina—vision and neurologic morbidity |
| Clear-cell renal cell carcinoma | Often multifocal/bilateral; nephron-sparing strategies |
| Pheochromocytoma / paraganglioma | Genotype correlates with risk (certain missense variants higher pheo risk) |
| Pancreatic cysts / NETs | Surveillance component |
| Endolymphatic sac tumors | Hearing loss clue |
| Epididymal / broad ligament cystadenomas | Benign but syndromic clues |
Counseling centers on lifelong coordinated surveillance (ophthalmology, CNS imaging, abdominal imaging, biochemical pheo screening) rather than a single prophylactic surgery. Distinguish VHL from other hereditary pheo/PGL syndromes (SDHx, RET, NF1, MAX, TMEM127) when the vignette is pheo-first.
Multiple Endocrine Neoplasia
MEN1 — MEN1
| “3 P” core | Detail |
|---|---|
| Parathyroid | Primary hyperparathyroidism—often multigland; earliest/most penetrant feature |
| Pituitary | Prolactinoma and other adenomas |
| Enteropancreatic neuroendocrine tumors | Gastrinoma (Zollinger-Ellison), insulinoma, others—malignant potential |
Additional features can include foregut carcinoids, adrenocortical lesions, and facial angiofibromas/collagenomas. Inheritance is AD. Management is biochemical and imaging surveillance plus targeted surgery—not one universal risk-reducing operation like MEN2 thyroidectomy.
MEN2 — RET
| Subtype | Hallmarks | Counseling anchor |
|---|---|---|
| MEN2A | Medullary thyroid carcinoma (MTC), pheo, hyperparathyroidism | RET codon correlates with MTC aggressiveness and prophylactic thyroidectomy timing |
| MEN2B (MEN3) | Very early/aggressive MTC, pheo, mucosal neuromas, marfanoid habitus, ganglioneuromatosis | Highest-risk RET variants (e.g., p.Met918Thr classically)—thyroidectomy discussed in infancy in specialty care |
| FMTC | MTC-predominant familial pattern | Still RET-related spectrum |
Prophylactic thyroidectomy timed by RET genotype is a defining MEN2 management concept and a frequent exam target. Always screen for pheochromocytoma before thyroid surgery when indicated—anesthesiology/surgical safety point genetic counselors should mention in preoperative counseling coordination.
Neurofibromatosis Type 1 and NF2-Related Schwannomatosis
| Feature | NF1 (NF1) | NF2 (NF2, Merlin) |
|---|---|---|
| Inheritance | AD; ~50% de novo | AD; frequent de novo |
| Cutaneous | Café-au-lait macules, skinfold freckling, cutaneous neurofibromas | Less “classic CALM” story; skin schwannomas possible |
| Hallmark tumors | Optic pathway glioma, plexiform neurofibromas, malignant peripheral nerve sheath tumor (MPNST) | Bilateral vestibular schwannomas; other schwannomas, meningiomas, ependymomas |
| Other | Learning differences, skeletal dysplasia, hypertension/pheo (less common than VHL/MEN2) | Hearing loss, balance problems dominate quality of life |
| Cancer counseling | MPNST risk education; breast cancer risk modestly increased in women—surveillance awareness | Tumor burden management; hearing preservation strategies |
Clinical diagnostic criteria (NIH/revised) still matter because many NF1 diagnoses are clinical; molecular confirmation helps atypical cases and cascade testing. Schwannomatosis (SMARCB1/LZTR1) is a related differential when vestibular schwannomas are absent.
Other High-Yield Predisposition Pointers (Brief)
| Syndrome | Gene(s) | One-line hallmark |
|---|---|---|
| Gorlin (nevoid BCC) | PTCH1, SUFU | Multiple basal cell carcinomas, jaw keratocysts, medulloblastoma risk (SUFU) |
| Cowden / PTEN hamartoma | PTEN | Macrocephaly, hamartomas, breast/thyroid/endometrial risks |
| Hereditary retinoblastoma | RB1 | Childhood retinoblastoma ± later sarcoma risk; radiation caution |
| Familial atypical mole–melanoma | CDKN2A | Melanoma ± pancreatic cancer risk discussions |
| Hereditary pheo/PGL | SDHB/C/D, etc. | SDHB higher malignancy concern |
Use these when a vignette sits outside HBOC/Lynch/LFS/VHL/MEN/NF—but master the primary five first.
Cross-Cutting Diagnostic and Counseling Strategy
- Hallmark tumor → syndrome shortlist (ACC child → LFS; MTC → RET; hemangioblastoma + RCC → VHL; bilateral vestibular schwannomas → NF2).
- Offer germline testing with pretest counseling about childhood-onset implications when relevant (TP53, RET MEN2B, RB1).
- Assign syndrome-specific surveillance (not generic “annual mammogram only”).
- Address risk-reducing surgery where established (notably genotype-guided thyroidectomy in MEN2; selective discussions in LFS breast risk).
- Implement cascade testing and coordinate multidisciplinary care (endo, neurosurgery, ophthalmology, oncology).
| Syndrome | Inheritance | Signature teaching tumor(s) | Signature management concept |
|---|---|---|---|
| LFS | AD (TP53) | Sarcoma, ACC, early breast, brain, leukemia | Comprehensive surveillance; radiation caution |
| VHL | AD (VHL) | Hemangioblastoma, ccRCC, pheo | Lifelong multi-organ surveillance |
| MEN1 | AD (MEN1) | Parathyroid, pituitary, pancreatic NET | Biochemical/imaging surveillance |
| MEN2 | AD (RET) | MTC ± pheo ± HPTH | Genotype-timed prophylactic thyroidectomy |
| NF1 | AD (NF1) | OPG, plexiforms, MPNST | Tumor vigilance; clinical + molecular diagnosis |
| NF2 | AD (NF2) | Bilateral vestibular schwannomas | Hearing-preserving tumor management |
These syndromes repay pattern recognition: one hallmark feature correctly identified often unlocks the entire counseling plan.
A 3-year-old is diagnosed with adrenocortical carcinoma. Which hereditary syndrome should be highest on the genetic counseling differential?
MUTYH-associated polyposis
NF2-related schwannomatosis because ACC is the hallmark tumor
Li-Fraumeni syndrome due to TP53, for which childhood ACC is a classic indication to evaluate
MEN1, because ACC is one of the “3 Ps”
Which tumor triad best matches von Hippel–Lindau disease for exam recognition?
CNS/retinal hemangioblastomas, clear-cell renal cell carcinoma, and pheochromocytoma
Medullary thyroid carcinoma, primary hyperparathyroidism, and mucosal neuromas only
Hundreds of colorectal adenomas, desmoid tumors, and CHRPE as the defining VHL set
Bilateral vestibular schwannomas, cutaneous neurofibromas, and optic pathway glioma
A young adult with medullary thyroid carcinoma and a pathogenic RET variant is counseled about family members. Which management concept is most specific to MEN2?
Universal early colectomy in the first decade for all RET carriers
Whole-body MRI every month starting at birth for all first-degree relatives without testing
Avoiding all endocrine surgery indefinitely because RET variants are low penetrance
Genotype-informed discussion of prophylactic thyroidectomy timing, with pheochromocytoma screening before indicated thyroid surgery
Which comparison between NF1 and NF2 is most accurate?
NF1 is autosomal recessive; NF2 is autosomal dominant
NF1 is characterized by café-au-lait macules and neurofibromas with risks such as optic pathway glioma and MPNST, whereas NF2 is dominated by bilateral vestibular schwannomas
Bilateral vestibular schwannomas are the diagnostic hallmark of NF1, not NF2
NF2 is caused by germline BRCA2 variants and managed with RRSO
Sections you finish are checked off in the contents.